REFERENCES
1. Sobenin IA, Galitsyna EV, Grechko AV, Orekhov AN. Small dense and desialylated low density lipoprotein in diabetic patients. Vessel Plus 2017;1:29-37.
2. Alipov VI, Sukhorukov VN, Karagodin VP, Grechko AV, Orekhov AN. Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference? Vessel Plus 2017;1:107-15.
3. Takahashi S. Triglyceride rich lipoprotein -LPL-VLDL receptor and Lp(a)-VLDL receptor pathways for macrophage foam cell formation. J Atheroscler Thromb 2017;24:552-9.
4. Lehti S, Nguyen SD, Belevich I, Vihinen H, Heikkilä HM, et al. Extracellular lipids accumulate in human carotid arteries as distinct three-dimensional structures and have proinflammatory properties. Am J Pathol 2018;188:525-38.
5. Orekhov AN, Ivanova EA, Bobryshev YV. Naturally occurring multiple-modified low-density lipoprotein. In: Ruiz M, editor. Blood lipids and lipoproteins. New York: Nova Science Publishers Inc.; 2015. pp. 13-54.
6. Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res 2018;114:540-50.
7. Kruth HS. Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density lipoprotein particles. Curr Opin Lipidol 2011;22:386-93.
8. Kruth HS, Jones NL, Huang W, Zhao B, Ishii I, et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J Biol Chem 2005;280:2352-60.
9. Orekhov AN, Ivanova EA, Melnichenko AA, Sobenin IA. Circulating desialylated low density lipoprotein. Cor Vasa 2017;59:e149-56.
10. Orekhov AN, Sobenin IA. Modified lipoproteins as biomarkers of atherosclerosis. Front Biosci (Landmark Ed) 2018;23:1422-44.
11. Orekhov AN, Tertov VV, Mukhin DN, Koteliansky VE, Glukhova MA, et al. Association of low-density lipoprotein with particulate connective tissue matrix components enhances cholesterol accumulation in cultured subendothelial cells of human aorta. Biochim Biophys Acta 1987;928:251-8.
12. Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, et al. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol 2018;187:1-9.
13. Sánchez-Quesada JL, Villegas S, Ordóñez-Llanos J. Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding. Curr Opin Lipidol 2012;23:479-86.
14. Orekhov AN, Andreeva ER, Bobryshev YV. Cellular mechanisms of human atherosclerosis: role of cell-to-cell communications in subendothelial cell functions. Tissue Cell 2016;48:25-34.
15. Orekhov AN, Oishi Y, Nikiforov NG, Zhelankin AV, Dubrovsky L, et al. Modified LDL particles activate inflammatory pathways in monocyte-derived macrophages: transcriptome analysis. Curr Pharm Des 2018;24:3143-51.
16. Nègre-Salvayre A, Augé N, Camaré C, Bacchetti T, Ferretti G, et al. Dual signaling evoked by oxidized LDLs in vascular cells. Free Radic Biol Med 2017;106:118-33.
17. Jongstra-Bilen J, Zhang CX, Wisnicki T, Li MK, White-Alfred S, et al. Oxidized low-density lipoprotein loading of macrophages downregulates TLR-Induced proinflammatory responses in a gene-specific and temporal manner through transcriptional control. J Immunol 2017;199:2149-57.
18. de la Paz Sánchez-Martínez M, Blanco-Favela F, Mora-Ruiz MD, Chávez-Rueda AK, Bernabe-García M, et al. IL-17-differentiated macrophages secrete pro-inflammatory cytokines in response to oxidized low-density lipoprotein. Lipids Health Dis 2017;16:196.
19. Orekhov AN, Ivanova EA. Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential. Phytomedicine 2016;23:1190-7.
20. Singh RK, Haka AS, Brumfield A, Grosheva I, Bhardwaj P, et al. Ceramide activation of RhoA/Rho kinase impairs actin polymerization during aggregated LDL catabolism. J Lipid Res 2017;58:1977-87.
21. Guo K, Hu L, Xi D, Zhao J, Liu J, et al. PSRC1 overexpression attenuates atherosclerosis progression in apoE(-/-) mice by modulating cholesterol transportation and inflammation. J Mol Cell Cardiol 2018;116:69-80.
22. Liu XX, Zhang XW, Wang K, Wang XY, Ma WL, et al. Kuwanon G attenuates atherosclerosis by upregulation of LXRα-ABCA1/ABCG1 and inhibition of NFκB activity in macrophages. Toxicol Appl Pharmacol 2018;341:56-63.
23. Ooi BK, Goh BH, Yap WH. Oxidative stress in cardiovascular diseases: involvement of Nrf2 antioxidant redox signaling in macrophage foam cells formation. Int J Mol Sci 2017; doi: 10.3390/ijms18112336.
24. Yang Y, Li X, Peng L, An L, Sun N, et al. Tanshindiol C inhibits oxidized low-density lipoprotein induced macrophage foam cell formation via a peroxiredoxin 1 dependent pathway. Biochim Biophys Acta Mol Basis Dis 2018;1864:882-90.
25. Liu Z, Zhu H, Dai X, Wang C, Ding Y, et al. Macrophage liver kinase B1 inhibits foam cell formation and atherosclerosis. Circ Res 2017;121:1047-57.
26. Srikakulapu P, Upadhye A, Rosenfeld SM, Marshall MA, McSkimming C, et al. Perivascular adipose tissue harbors atheroprotective IgM-producing B cells. Front Physiol 2017;8:719.
27. Srikakulapu P, McNamara CA. B cells and atherosclerosis. Am J Physiol Heart Circ Physiol 2017;312:H1060-7.
28. Yan D, He Y, Dai J, Yang L, Wang X, et al. Vascular endothelial growth factor modified macrophages transdifferentiate into endothelial-like cells and decrease foam cell formation. Biosci Rep 2017; doi: 10.1042/BSR20170002.
29. Maier A, Wu H, Cordasic N, Oefner P, Dietel B, et al. Hypoxia-inducible protein 2 Hig2/Hilpda mediates neutral lipid accumulation in macrophages and contributes to atherosclerosis in apolipoprotein E-deficient mice. FASEB J 2017;31:4971-84.
30. Chen L, Zhang J, Deng X, Liu Y, Yang X, et al. Lysophosphatidic acid directly induces macrophage-derived foam cell formation by blocking the expression of SRBI. Biochem Biophys Res Commun 2017;491:587-94.
31. Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med 2005;165:138-45.
32. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45.
33. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344.
34. Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc Diagn Ther 2017;7(Suppl 1):S4-10.
35. Kooter AJ, Kostense PJ, Groenewold J, Thijs A, Sattar N, et al. Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741-5.
36. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res 2012;110:658-62.
37. Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012;58:72-82.
38. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013;173:664-71.
39. Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, et al. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb 1991;11:316-26.
40. Tsimikas S, Miller YI. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 2011;17:27-37.
41. Ivanova EA, Bobryshev YV, Orekhov AN. LDL electronegativity index: a potential novel index for predicting cardiovascular disease. Vasc Health Risk Manag 2015;11:525-32.
42. Akyol S, Lu J, Akyol O, Akcay F, Armutcu F, et al. The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications. Trends Cardiovasc Med 2017;27:239-46.
43. Sobenin IA, Salonen JT, Zhelankin AV, Melnichenko AA, Kaikkonen J, et al. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value. Biomed Res Int 2014;2014:205697.
44. Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN. Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis. J Clin Immunol 2013;33:489-95.
45. Orekhov AN, Kalenich OS, Tertov VV, Novikov ID. Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue React 1991;13:233-6.
46. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, et al. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007;190:359-69.
47. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G; VADT Group of Investigators. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications 2016;30:693-9.
48. Orekhov AN, Bobryshev YV, Sobenin IA, Melnichenko AA, Chistiakov DA. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. Int J Mol Sci 2014;15:12807-41.
49. Sobenin IA, Orekhova VA, Melnichenko AА, Bobryshev YV, Orekhov AN. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int J Cardiol 2013;166:747-8.
50. Leopold JA. Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis 2015;26:176-83.
51. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
52. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012;14:1-10.
53. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-405.
54. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
55. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
56. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
57. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
58. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
59. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
60. Chen Z, Peto R, Collins R, MacMahon S, Lu J, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-82.
61. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.
62. Kijani S, Vázquez AM, Levin M, Borén J, Fogelstrand P. Intimal hyperplasia induced by vascular intervention causes lipoprotein retention and accelerated atherosclerosis. Physiol Rep 2017; doi: 10.14814/phy2.13334.
63. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016;27:473-83.
64. Chistiakov DA, Myasoedova VA, Revin VV, Orekhov AN, Bobryshev YV. The phenomenon of atherosclerosis reversal and regression: lessons from animal models. Exp Mol Pathol 2017;102:138-45.
65. Orekhov AN. Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention. Curr Pharm Des 2013;19:5909-28.
66. Zakiev ER, Nikiforov NG, Orekhov AN. Cell-based models for development of antiatherosclerotic therapies. Biomed Res Int 2017;2017:5198723.
67. Orekhov AN, Tertov VV, Novikov ID, Krushinsky AV, Andreeva ER, et al. Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme isolated and cultured cells. Exp Mol Pathol 1985;42:117-37.
68. Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN. Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis 1986;60:101-10.
69. Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, et al. Anti-atherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov 2013;8:56-66.
70. Kirichenko TV, Sobenin IA, Nikolic D, Rizzo M, Orekhov AN. Anti-cytokine therapy for prevention of atherosclerosis. Phytomedicine 2016;23:1198-210.
71. Kirichenko TV, Myasoedova VA, Orekhova VA, Ravani AL, Nikitina NA, et al. Phytoestrogen-rich natural preparation for treatment of climacteric syndrome and atherosclerosis prevention in perimenopausal women. Phytother Res 2017;31:1209-14.
72. Slevin M, Ahmed N, Wang Q, McDowell G, Badimon L. Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential? Vasc Cell 2012;4:9.
